ProLynx
Prolynx is developing a next-generation portfolio of extended-duration therapeutic candidates designed for once-monthly and once-quarterly dosing.
Private Company
Total funding raised: $18M
About
Prolynx is developing a next-generation portfolio of extended-duration therapeutic candidates designed for once-monthly and once-quarterly dosing.
Drug Delivery
Funding History
3Total raised:$18M
Grant$500K
Series A$15M
Seed$2.5M